Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · June 20, 2024

Cardiorenal Outcomes of Empagliflozin in Patients With HFpEF Across the BMI Spectrum

European Journal of Heart Failure


Additional Info

European Journal of Heart Failure
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial
Eur. J. Heart Fail 2024 Apr 01;26(4)900-909, N Sattar, J Butler, MMY Lee, J Harrington, A Sharma, F Zannad, G Filippatos, S Verma, JL Januzzi, JP Ferreira, SJ Pocock, E Pfarr, AP Ofstad, M Brueckmann, M Packer, SD Anker

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading